A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/29/2004	CA2673334A1 Oral extended-release composition
12/29/2004	CA2613021A1 Fluvastatin sodium crystal form lxxx, processes for preparing, compositions and methods of using
12/29/2004	CA2613013A1 Fluvastatin sodium crystal form lxxiii, processes for preparing, compositions and methods of using
12/29/2004	CA2610635A1 Fluvastatin sodium crystal form lxxxvii, processes for preparing, compositions and methods of using
12/29/2004	CA2610633A1 Fluvastatin sodium crystal form lxxix, processes for preparing, compositions and methods of using
12/29/2004	CA2534094A1 Glycosidase inhibitors and methods of synthesizing same
12/29/2004	CA2532473A1 Amino acid supplementation for a healthy microbiota ecosystem
12/29/2004	CA2530736A1 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug
12/29/2004	CA2530461A1 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors
12/29/2004	CA2530181A1 Novel imidazopyridine compound ii with therapeutic effect
12/29/2004	CA2530058A1 Mucin synthesis inhibitors
12/29/2004	CA2530004A1 Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
12/29/2004	CA2529963A1 Pharmaceutical compositions based on diclofenac derivate
12/29/2004	CA2529949A1 Antiviral compounds and methods
12/29/2004	CA2529860A1 Ophthalmic composition
12/29/2004	CA2529859A1 Fluvastatin sodium crystal forms xiv, lxxiii ,lxxix, lxxx and lxxxvii, processes for preparing them, compositions containing them and methods of using them
12/29/2004	CA2529854A1 Methods for inhibiting or reversing tau filament fibrillization
12/29/2004	CA2529847A1 Antiviral compositions and methods of using the same
12/29/2004	CA2529805A1 Gaboxadol for treating depression and other affective disorders
12/29/2004	CA2529774A1 Resolution of .alpha.-(phenoxy)phenylacetic acid derivatives
12/29/2004	CA2529754A1 Medical devices and methods for regulating the tissue response to vascular closure devices
12/29/2004	CA2529544A1 Amine salts of (-)-2-{2-(4-hydroxyphenyl) ethyl!-thio}-3-4-(2-{4-(methylsulfonyl)oxy] phenoxy}ethyl)phenyl] propanoic acid and there use in medicine
12/29/2004	CA2529535A1 Memantine oral dosage forms
12/29/2004	CA2529528A1 Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
12/29/2004	CA2529524A1 Substituted piperidine compounds and methods of their use
12/29/2004	CA2529501A1 Rate controlled release of a pharmaceutical agent in a biodegradable device
12/29/2004	CA2529500A1 Prodrugs of heteroaryl compounds
12/29/2004	CA2529462A1 An agent for improving physiological motor functions
12/29/2004	CA2529409A1 Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
12/29/2004	CA2529406A1 New use i
12/29/2004	CA2529317A1 Supplement for restoring growth hormone levels
12/29/2004	CA2529298A1 Indole derivatives as serotonin reuptake inhibitors
12/29/2004	CA2529297A1 Therapeutic agents
12/29/2004	CA2529287A1 Method for inhibiting the growth of antibiotic-resistant of bacteria by using pentane-1,5-diol
12/29/2004	CA2529268A1 Pharmaceutical formulations of amyloid inhibiting compounds
12/29/2004	CA2529254A1 Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
12/29/2004	CA2529253A1 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
12/29/2004	CA2529252A1 Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
12/29/2004	CA2529251A1 Potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid and their use in medicine
12/29/2004	CA2529250A1 Chinazoline derivatives as aurora kinase inhibitors
12/29/2004	CA2529161A1 Quinolyl amide derivatives as ccr-5 antagonists
12/29/2004	CA2529142A1 Rna interferases and methods of use thereof
12/29/2004	CA2529056A1 Combinations of tumor-associated antigens in compositions for various types of cancers
12/29/2004	CA2529055A1 Improved absorption of fat-soluble nutrients
12/29/2004	CA2529051A1 Vaccines, immunotherapeutics and methods for using the same
12/29/2004	CA2528899A1 Flupirtin injectable galenic form
12/29/2004	CA2528771A1 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
12/29/2004	CA2528718A1 Treatment of amd with combination of ingredients
12/29/2004	CA2528711A1 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
12/29/2004	CA2528603A1 Thienopyridone derivatives as kinase inhibitors
12/29/2004	CA2528602A1 Thienopyridone derivatives as kinase inhibitors
12/29/2004	CA2528538A1 Dual function compounds and uses thereof
12/29/2004	CA2528317A1 Hydroxamate sulfonamides as cd23 shedding inhibitors
12/29/2004	CA2528316A1 Hydroxamate sulfonamides as cd23 shedding inhibitors
12/29/2004	CA2528234A1 Propionic acid derivatives useful in the treatment of lipid disorders
12/29/2004	CA2527806A1 Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/29/2004	CA2527765A1 Use of isomalt as prebiotic
12/29/2004	CA2527533A1 Mitotic kinesin inhibitors
12/29/2004	CA2527121A1 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
12/29/2004	CA2526642A1 Compositions in the form of a spray comprising a pharmaceutical agent at least one volatile silicone and a non-volatile oily phase
12/29/2004	CA2526617A1 Diaryl ureas with kinase inhibiting activity
12/29/2004	CA2526563A1 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
12/29/2004	CA2526423A1 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
12/29/2004	CA2526103A1 Cannabinoid derivatives, methods of making, and use thereof
12/29/2004	CA2525713A1 Benzofuran inhibitors of factor viia
12/29/2004	CA2524739A1 Metronidazole-based green tinted topical pharmaceutical composition
12/29/2004	CA2524700A1 N-substituted 6,8-dialkoxy-1,2,3,4-tetrahydro-1h-isoquinoline as potassium channels modulators
12/29/2004	CA2524567A1 Compositions and methods for the diagnosis and treatment of tumors of glial origin
12/29/2004	CA2524027A1 Immunosuppressant compounds and compositions
12/29/2004	CA2523015A1 Guanidino-substituted quinazolinone compounds as mc4-r agonists
12/28/2004	US6835837 Antiallergens; antiinflammatory agents; skin disorders; osteoporosis
12/28/2004	US6835836 Dichlorinated heterocyclic compounds and methods of synthesis
12/28/2004	US6835829 Purification process
12/28/2004	US6835826 Acid resistance, stability; telomerase inhibitor
12/28/2004	US6835819 Sequences and their use
12/28/2004	US6835817 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
12/28/2004	US6835755 Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
12/28/2004	US6835754 Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example
12/28/2004	US6835753 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt
12/28/2004	US6835751 Bicyclic amino acids as pharmaceutical agents
12/28/2004	US6835750 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
12/28/2004	US6835749 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
12/28/2004	US6835748 Treatment of ocular disorders
12/28/2004	US6835745 Treating or inhibiting osteoporosis or bone demineralization, inflammatory bowel disease, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometriosis, endometrial cardiovascular disease, Alzheimer's disease
12/28/2004	US6835744 3,3-substituted indoline derivatives
12/28/2004	US6835742 Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
12/28/2004	US6835740 Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride
12/28/2004	US6835739 Benzamides and related inhibitors of factor Xa
12/28/2004	US6835738 Phenylalanine enamide derivatives
12/28/2004	US6835737 Quinoline inhibitors of cGMP phosphodiesterase
12/28/2004	US6835736 Discorhabdin compounds and methods of use
12/28/2004	US6835735 Anticancer, tyrosine kinase inhibitors
12/28/2004	US6835734 1,3-dioxolanes with antitussive activity
12/28/2004	US6835732 Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics
12/28/2004	US6835731 Chemokine receptor binding heterocyclic compounds
12/28/2004	US6835730 4-heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof
12/28/2004	US6835729 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
12/28/2004	US6835728 Drug combination for the treatment of depression and related disorders comprising mirtazapine
12/28/2004	US6835727 Bone disorders; osteoporosis; rheumatic diseases
12/28/2004	US6835726 For therapy of viral infections, particularly human Cytomegalovirus infection

1 ... 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862 4863 4864 4865 ... 7860